Menu Search
Equities

Organon & Co

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0A9W:LSE

Organon & Co

Actions
  • Price (USD)8.10
  • Today's Change-0.049 / -0.60%
  • Shares traded97.41k
  • 1 Year change-45.92%
  • Beta0.5566
Data delayed at least 20 minutes, as of Feb 06 2026 17:17 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

  • Revenue in USD (TTM)6.30bn
  • Net income in USD501.00m
  • Incorporated2020
  • Employees10.00k
  • Location
    Organon & Co30 Hudson Street, Fl 33JERSEY CITY 07302United StatesUSA
  • Phone+1 (551) 430-6000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.organon.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.